- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pfizer eyes USD 10 billion- USD 15 billion in potential revenue from mRNA vaccines by 2030
New York: Pfizer Inc said on Monday that annual revenue from its mRNA vaccine portfolio could reach $10 billion to $15 billion by 2030, alleviating fears of a sharp hit to its topline from an expected decline in COVID vaccine demand and patent expirations.
Shares of the New York City-based company rose nearly 2% to $52.59 during afternoon trade and helped lift U.S. stock indexes higher.
The company's revenue is expected to top $100 billion this year- more than double the pre-pandemic level - helped by strong demand for its COVID-19 vaccine and oral treatment Paxlovid.
In November, Pfizer had raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion.
But COVID-related sales are expected to drop sharply over the next few years, and Pfizer also faces the loss of patent protections for some big-selling drugs after 2025, such as cancer treatment Ibrance and arthritis drug Xeljanz.
Pfizer expects to lose $17 billion in annual sales between 2025 and 2030 due to the patent expirations, Chief Commercial Officer Angela Hwang said in an investor presentation, where the company provided revenue expectations for its drugs and vaccines.
The company has been investing heavily into its mRNA pipeline and said the manufacturing capacity for Comirnaty, its COVID-19 vaccine developed with German partner BioNTech SE, leaves it uniquely positioned to deliver other mRNA shots globally.
Analysts expect COVID-19 vaccine revenues to drop sharply beginning in 2023 and see sales of Pfizer's Comirnaty at around $6.7 billion in 2027, according to Refinitiv.
Pfizer did not provide a breakdown of sales expectations from different mRNA vaccine, but said sales from its respiratory syncytial virus (RSV) vaccine candidate, to be launched in 2023, could peak in 2027 and reach more than $2 billion.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751